Transcend Medical is focused on the development of minimally invasive medical devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. Over 4 million people in the U.S. and roughly 65 million worldwide are afflicted with the disease today, and the numbers are expected to grow to nearly 6 million in the U.S. and over 70 million worldwide by the year 2015.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/02/14 | $22,000,000 | Series C |
Canaan Partners Finistere Ventures HLM Venture Partners Kaiser Permanente Ventures Latterell Venture Partners Split Rock Partners Technology Partners | undisclosed |
